IL17RB and acute myeloid leukemia: Similar results were recently obtained in leukemic cells by Guo et al., who demonstrated that the IL-17RB pathway promotes the survival of MOLM-13 AML cells by increasing ERK and NF-KB phosphorylation and Bcl-2 level and consequently, resistance to the purine analog Ara-C, the frontline chemotherapeutic agent for AML (38).